Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 13c, Beats on Revenues; Offers FY17 OpEx Guidance

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.70), $0.13 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $305 thousand versus the consensus estimate of $300 thousand.

Financial Guidance

Today the Company provided operating expense guidance for the third quarter and full year 2017. For the third quarter and full year 2017, research and development expenses are expected to be $12.0 to $14.0 million and $46.0 to $51.0 million, respectively, and total operating expenses are expected to be $16.0 to $18.0 million and $63.0 to $68.0 million, respectively.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• MetLife estimates Q2 2026 variable investment income below annual pace
• Gorilla Technology raises Q2 2026 revenue outlook to $44M